A case report of long term bevacizumab treatment in multiresistant ovarian cancer

Anette Kargo, Parvin Adimi, Karina Dahl Steffensen


Treatment of multiresistant ovarian cancer is palliative and patients have needs for less toxic treatment. Anti-angiogenic treatments have a less toxic profile, and bevacizumab has shown improvement of progression free survival (PFS) in front-line trials. Bevacizumab is generally introduced in combination with chemotherapy; however this case report will describe the use of single-agent bevacizumab for more than five years (102 cycles) in a patient with relapse of advanced ovarian cancer.


Ovarian cancer, Bevacizumab

Full Text:



Available from http://eu-cancer.iarc.fr/EUCAN/CancerOne.aspx?Cancer=27&Gender=2

Luvero D, Milani A, Ledermann JA. Treatment options in recurrent overaian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6(5): 229–39.

Monk BJ, Pujade-Lauraine E, Burger RA. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease. Ann Oncol. 2013;24(suppl.10):x53-8.

Available from http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000582/WC500112811.pdf

Burger RA, Brady MF, Bookman MA et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med. 2011;365:2473-83.

Perren TJ, Swart AM, Pfisterer J et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N Engl J Med. 2011;365:2484-96.

Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab Combined With Chemotherapy For Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. J Clin Oncol. 32:1302-8.

Aghajanian C, Blank SV, Goff BA et al. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2012;30:2039-45.

Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-6.

Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25(33):5165-71.

DOI: http://dx.doi.org/10.14319/ijcto.42.14

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.


International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)

© International Journal of Cancer Therapy and Oncology (IJCTO)

To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.


Number of visits since October, 2013